Hepatitis B Virus (Hbv) Therapeutics Us Drug Market Share, Size, Trends, Growth and Analysis

Summary

Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition. In addition, patients with chronic hepatitis B are at a high risk of developing life-threatening complications including liver cirrhosis and hepatocellular carcinoma (HCC). In 2010, an estimated 786,000 HBV-related deaths occurred worldwide.

Available treatment for chronic hepatitis B focuses on viral suppression, and include oral nucleos(t)ide analogues (NAs) and pegylated interferon (PEG-IFN). The two therapy classes have distinctive strengths and weaknesses. Nevertheless, most patients are using long-term NA treatment, and suffer from issues such as high accumulated treatment cost and low compliance.

Browse Detail Report With TOC @

https://marketreportscenter.com/reports/277895/hepatitis

The US chronic hepatitis B therapeutics market was valued at $772.8m in 2014. The main driver of the US market over the forecast period will be the launch of novel therapies: most notably, the three adjunct therapies. These agents are aimed to be used alongside marketed oral NAs, and to improve the immunological cure rate, which is measured by the clearance or seroconversion of HBsAg and sustained HBV DNA suppression.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Overview of HBV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in the US from 2014-2024.

- Analysis of the...